|
|
???tair.name??? >
???browser.page.title.author???
|
"izumi n"???jsp.browse.items-by-author.description???
Showing items 1-7 of 7 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國立成功大學 |
2023 |
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
|
Lim, Y.-S.;Chan, H.L.Y.;Ahn, S.H.;Seto, W.K.;Ning, Q.;Agarwal, K.;Janssen, H.L.A.;Pan, C.Q.;Chuang, W.L.;Izumi, N.;Fung, S.;Shalimar;Brunetto, M.;Hui, A.J.;Chang, T.-T.;Lim, S.G.;Abramov, F.;Flaherty, J.F.;Wang, H.;Yee, L.J.;Kao, J.-H.;Gane, E.;Hou, J.;Buti, M. |
| 臺大學術典藏 |
2021-09-01T01:54:13Z |
Liver cancer working group report
|
Kudo M.; Han K.H.; Kokudo N.; ANN-LII CHENG; Choi B.I.; Furuse J.; Izumi N.; Park J.-W.; Poon R.T.; Sakamoto M. |
| 臺大學術典藏 |
2021-08-31T06:29:48Z |
Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study
|
ANN-LII CHENG; Kang Y.-K.; He A.R.; Lim H.Y.; Ryoo B.-Y.; Hung C.-H.; Sheen I.-S.; Izumi N.; Austin T.; Wang Q.; Greenberg J.; Shiratori S.; Beckman R.A.; Kudo M. |
| 臺大學術典藏 |
2021-08-31T06:29:32Z |
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
|
Kudo M.; ANN-LII CHENG; Park J.-W.; Park J.H.; Liang P.-C.; Hidaka H.; Izumi N.; Heo J.; Lee Y.J.; Sheen I.-S.; Chiu C.-F.; Arioka H.; Morita S.; Arai Y. |
| 臺大學術典藏 |
2021-08-31T06:29:20Z |
Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma
|
Alsina A.; Kudo M.; Vogel A.; ANN-LII CHENG; Tak W.Y.; Ryoo B.-Y.; Evans T.R.J.; L?pez L?pez C.; Daniele B.; Misir S.; Ren M.; Izumi N.; Qin S.; Finn R.S. |
| 臺大學術典藏 |
2020-08-11T08:36:43Z |
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
|
Kudo M.;Cheng A.-L.;Park J.-W.;Park J.H.;Po-Chin Liang;Hidaka H.;Izumi N.;Heo J.;Lee Y.J.;Sheen I.-S.;Chiu C.-F.;Arioka H.;Morita S.;Arai Y.; Kudo M.; Cheng A.-L.; Park J.-W.; Park J.H.; PO-CHIN LIANG; Hidaka H.; Izumi N.; Heo J.; Lee Y.J.; Sheen I.-S.; Chiu C.-F.; Arioka H.; Morita S.; Arai Y. |
| 臺大學術典藏 |
2018-09-10T18:04:58Z |
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
|
Kudo, M.;Cheng, A.-L.;Park, J.-W.;Park, J.H.;Liang, P.-C.;Hidaka, H.;Izumi, N.;Heo, J.;Lee, Y.J.;Sheen, I.-S.;Chiu, C.-F.;Arioka, H.;Morita, S.;Arai, Y.; PO-CHIN LIANG; ANN-LII CHENG |
Showing items 1-7 of 7 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
